Anti-RNA virus activity of polyoxometalates

Biomed Pharmacother. 2006 Jun;60(5):211-9. doi: 10.1016/j.biopha.2006.03.009. Epub 2006 May 24.

Abstract

The anti-RNA virus activity of polyoxometalates (POM) is reviewed, with a special emphasis on the anti-respiratory virus activities. There are many causative agents of acute viral respiratory infections; and it is rather difficult to identify the relevant agent in a given case by rapid clinical means. During acute progress of infection before the definitive diagnosis is obtained physicians need to prescribe certain broad spectrum anti-viral drugs. A titanium containing polyoxotungstate, PM-523 exhibited potent anti-influenza virus (FluV) A and anti-respiratory syncytial virus (RSV) activities in vitro. Therapeutic effect of FluV A infected mice with aerosol inhalation of PM-523 was proven. A vanadium substituted polyoxotungstate, PM-1001 has antiviral activity against FluV A, RSV, parainfluenza virus (PfluV) type 2, Dengue fiver virus, HIV-1 and SARS coronavirus in vitro. Thus, POMs have been proven to be broad spectrum and non-toxic anti-RNA virus agents in both in vitro and in vivo experiments and are promising candidates for first-line therapeutics in acute respiratory diseases.

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • Coronavirus / drug effects
  • Drug Resistance, Viral
  • Drug Synergism
  • Humans
  • Influenza, Human / drug therapy
  • Orthomyxoviridae / drug effects
  • RNA Viruses / drug effects*
  • Ribavirin / pharmacology
  • Ribavirin / therapeutic use
  • Titanium / therapeutic use
  • Tungsten Compounds / pharmacology*
  • Tungsten Compounds / therapeutic use
  • Vanadium Compounds / therapeutic use
  • Virus Diseases / drug therapy

Substances

  • Antiviral Agents
  • Tungsten Compounds
  • Vanadium Compounds
  • polyoxometalate I
  • Ribavirin
  • Titanium